Table 3.

Subgroup analysis

Subgroup	Primary prevention	Secondary prevention
	Icosapent ethyl	Icosapent ethyl	Evolocumab	Alirocumab
Base case	19,485	13,285	85,193	54,211
Age
< 65 years	14,368	8809	88,474	59,567
≥ 65 years	36,383	37,071	85,193	47,632
Baseline triglyceride ≥ 200 mg/dL and HDL-C ≤ 35 mg/dLa
No	23,288	17,226	NR	NR
Yes	12,166	7131	NR	NR
Baseline LDL-C ≥ 100 mg/dLb
No	NR	NR	107,362	62,001
Yes	NR	NR	63,600	44,851
Baseline high-sensitivity CRP
≤ 2 mg/L	14,882	9221	74,106	49,660
> 2 mg/LL	25,694	20,048	99,947	59,567

ICER (£ per QALY) are presented for different patient populations. Costs in 2021 Great Britain Pounds (£)

CRP c-reactive protein, CVD cardiovascular disease, HDL-C high-density-lipoprotein-cholesterol, ICER incremental cost-effectiveness ratio, LDL-C low-density-lipoprotein-cholesterol, NR not reported, QALY quality-adjusted life year

^aA triglyceride level of 200 mg/dL is equivalent to 2.3 mmol/L. A HDL-C level of 35 mg/dL is equivalent to 0.9 mmol/LL

^bA LDL-C level of 100 mg/dL is equivalent to 2.6 mmol/LL